In an exclusive conversation with Deccan Chronicle, Dr. G Vikram Kumar sheds light on the complexities of hemophilia, its impact on patients’ lives, and the recent breakthroughs in the ...
Columnist Alliah Czarielle offers insight into how obesity and fat-shaming can affect people with hemophilia, particularly young folks.
The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.
Females can also be affected but tend to have milder symptoms. People with mild hemophilia A may have prolonged bleeding events after a surgical procedure, dental work, or a serious injury.
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Researchers reviewed data from 14 hemophilia patients treated with Sevenfact to better understand its real-world safety and ...
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
The Food and Drug Administration approved Pfizer’sPFE-0.17%decrease; red down pointing triangle Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback